<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931164</url>
  </required_header>
  <id_info>
    <org_study_id>32164</org_study_id>
    <secondary_id>103932</secondary_id>
    <nct_id>NCT00931164</nct_id>
  </id_info>
  <brief_title>Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)</brief_title>
  <acronym>AHC-SO</acronym>
  <official_title>Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alternating Hemiplegia of Childhood Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      WHO: The investigators are recruiting children and young adults to participate in a research
      study who:

        1. Have been diagnosed with Alternating Hemiplegia of Childhood (AHC)

        2. Are between the ages of 6 months - 25 years old

        3. Have at least three 10-minute-long AHC episodes during a typical week

        4. Can commit to 12 weeks of completing of a daily log describing AHC episodes and to a
           multi-night hospital stay at the University of Utah Center for Clinical and
           Translational Science (CCTS)

      WHY: The goal of this study is to evaluate whether the study drug can safely and effectively
      decrease AHC episodes and improve the quality of life of individuals with AHC.

      WHAT and WHERE: This study involves at least 12 weeks of completing and submitting daily AHC
      Episode Logs and a five-day hospital stay at the University of Utah CCTS.

      There are 4 phases of the study, and they include:

        1. Six weeks of daily log completion prior to starting study drug

        2. Five day stay at the University of Utah CCTS

        3. Six additional weeks of daily log completion while using study drug at home

        4. One day clinic visit to the University of Utah for follow up

      COMPENSATION:

      There is no fee to participate. All procedures performed specifically for this study will be
      covered by the study and will not be billed to you or your insurance company.

      The study drug will be dispensed to you free of charge. Meals and lodging at the study site
      will be provided free of charge for the study participant and one care provider.
      Additionally, the research team will assist subjects with booking and obtaining free
      transportation, such as an airline tickets, to and from the study site.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Duration of AHC Episodes</measure>
    <time_frame>Week 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Safety Data During 5-day Hospitalization for Drug Dose Identification</measure>
    <time_frame>Week 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Reported Side Effects During Home Drug Maintenance Phase</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Percentage of Time That Functional Status is Affected Due to Episodes</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood and Behavior Questionnaires</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Skills Questionnaires</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Tests</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Alternating Hemiplegia of Childhood</condition>
  <arm_group>
    <arm_group_label>Sodium oxybate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate</intervention_name>
    <description>dosage is by weight</description>
    <arm_group_label>Sodium oxybate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria.

          -  AHC classic criteria:

               -  Onset of symptomatology prior to 18 months of age

               -  Repeated attacks of hemiplegia involving either side of the body

               -  Paroxysmal disturbances, including tonic or dystonic spells, oculomotor
                  abnormalities, and various autonomic phenomena, during hemiplegic bouts or in
                  isolation

               -  Episodes of bilateral hemiplegia or quadriplegia starting either as
                  generalization of a hemiplegic episode or bilateral from the beginning

               -  Immediate disappearance of symptoms upon sleeping, with possible resumption 10-20
                  minutes after waking

               -  Evidence of developmental delay and neurologic abnormalities including
                  choreoathetosis, dystonia, or ataxia

        In addition:

          -  Provision of a complete daily event log for 6 weeks prior to initiation of sodium
             oxybate therapy, including the: (1) frequency, (2) duration, (3) type, (4) severity of
             episodes, and (5) therapies, if any, used in an attempt to abort the episode

          -  Ages 6 months to 25 years at the time of study enrollment

          -  Minimum of 3 AHC episodes weekly, lasting at least 10 minutes each, on average prior
             to study enrollment

          -  Brain neuroimaging studies excluding alternative etiology for symptoms

          -  Documented absence of epileptiform features on EEG during typical ictal events

          -  Ability of primary caregivers of study participants to submit online daily AHC Episode
             Logs indicating frequency and duration of ictal episodes over the entire study period

          -  Written informed consent from parents/guardians and assent from children 7 years or
             older

          -  Girls/women &gt; 12 years of age will be required to be on birth control continuously if
             they are considered at risk to become pregnant. Those not on birth control will be
             required to have a screening pregnancy test at baseline, and to confirm their
             willingness to practice birth control or abstain from sexual activity for the duration
             of treatment with study medication.

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from participation.

          -  History of hepatic insufficiency, renal insufficiency, significant respiratory
             disease, cardiac arrhythmia, congenital heart defect, hypertension, or ischemic stroke

          -  History of allergy/sensitivity to sodium oxybate

          -  Use of sodium oxybate within 30 days of study enrollment

          -  Serious illness requiring systemic treatment and/or hospitalization within two weeks
             prior to study enrollment

          -  Change in neurologic medication regimen within 30 days of study enrollment.

          -  Inability to stay at the Center for Clinical and Translational Science (CCTS) for 5
             days due to behavioral issues

          -  Unwillingness or inability to travel to study site during the necessary 1 week
             titration period to determine the most appropriate dose of GHB for subsequent
             administration

          -  Noncompliance with AHC Episode Log or study visit requirements

          -  Sleep apnea not adequately treated with C-PAP and oxygen saturation monitoring prior
             to drug therapy initiation

          -  Succinic semialdehyde dehydrogenase deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn J. Swoboda, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah/Primary Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Addolorato G, Cibin M, Capristo E, Beghe F, Gessa G, Stefanini GF, Gasbarrini G. Maintaining abstinence from alcohol with gamma-hydroxybutyric acid. Lancet. 1998 Jan 3;351(9095):38. Erratum in: Lancet 1998 Mar 7;351(9104):760. Caprista E [corrected to Capristo E].</citation>
    <PMID>9433435</PMID>
  </reference>
  <reference>
    <citation>A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003 Feb 1;26(1):31-5.</citation>
    <PMID>12627729</PMID>
  </reference>
  <reference>
    <citation>Arnold DL, Silver K, Andermann F. Evidence for mitochondrial dysfunction in patients with alternating hemiplegia of childhood. Ann Neurol. 1993 Jun;33(6):604-7.</citation>
    <PMID>8498840</PMID>
  </reference>
  <reference>
    <citation>Bourgeois M, Aicardi J, Goutières F. Alternating hemiplegia of childhood. J Pediatr. 1993 May;122(5 Pt 1):673-9. Review.</citation>
    <PMID>8496742</PMID>
  </reference>
  <reference>
    <citation>Bourgeois M, Aicardi J. The treatment of alternating hemiplegia of childhood with flunarizine: experience with 17 patients. Alternating Hemiplegia of Childhood, edited by F Andermann, J Aicardi, and F Vigevano. 1995;191-194.</citation>
  </reference>
  <reference>
    <citation>Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, Del Re A, Comaschi C, Andreone P, Trevisani F, Bernardi M; Alcohol Treatment Study Group. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol. 2007 Dec;17(12):781-9. Epub 2007 Jul 3.</citation>
    <PMID>17611081</PMID>
  </reference>
  <reference>
    <citation>Casaer P. Flunarizine in alternating hemiplegia in childhood. An international study in 12 children. Neuropediatrics. 1987 Nov;18(4):191-5.</citation>
    <PMID>3320807</PMID>
  </reference>
  <reference>
    <citation>Casaer P, Azou M. Flunarizine in alternating hemiplegia in childhood. Lancet. 1984 Sep 8;2(8402):579.</citation>
    <PMID>6147627</PMID>
  </reference>
  <reference>
    <citation>Defossez M, Le Bec G, Sancier A, Manelfe C, Espagno MT, Bouzat A, Sevely A. [Neuro-sedation and cranial C.-T. scan in infants and children (author's transl)]. Anesth Analg (Paris). 1979;36(11-12):525-9. French.</citation>
    <PMID>554477</PMID>
  </reference>
  <reference>
    <citation>Ferrara SD, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F, Palatini P. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol. 1999 Jan;54(11):821-7.</citation>
    <PMID>10027654</PMID>
  </reference>
  <reference>
    <citation>Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005 Oct;20(10):1330-7.</citation>
    <PMID>15986420</PMID>
  </reference>
  <reference>
    <citation>Haan J, Kors EE, Terwindt GM, Vermeulen FL, Vergouwe MN, van den Maagdenberg AM, Gill DS, Pascual J, Ophoff RA, Frants RR, Ferrari. Alternating hemiplegia of childhood: no mutations in the familial hemiplegic migraine CACNA1A gene. Cephalalgia. 2000 Oct;20(8):696-700.</citation>
    <PMID>11167897</PMID>
  </reference>
  <reference>
    <citation>Hunter AS, Long WJ, Ryrie CG. An evaluation of gamma-hydroxybutyric acid in paediatric practice. Br J Anaesth. 1971 Jun;43(6):620-8.</citation>
    <PMID>5089942</PMID>
  </reference>
  <reference>
    <citation>Jiang W, Chi Z, Ma L, Du B, Shang W, Guo H, Wu W. Topiramate: a new agent for patients with alternating hemiplegia of childhood. Neuropediatrics. 2006 Aug;37(4):229-33.</citation>
    <PMID>17177149</PMID>
  </reference>
  <reference>
    <citation>Jen J, Yue Q, Nelson SF, Yu H, Litt M, Nutt J, Baloh RW. A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia. Neurology. 1999 Jul 13;53(1):34-7.</citation>
    <PMID>10408533</PMID>
  </reference>
  <reference>
    <citation>Kanavakis E, Xaidara A, Papathanasiou-Klontza D, Papadimitriou A, Velentza S, Youroukos S. Alternating hemiplegia of childhood: a syndrome inherited with an autosomal dominant trait. Dev Med Child Neurol. 2003 Dec;45(12):833-6. Erratum in: Dev Med Child Neurol. 2004 Apr;46(4):288.</citation>
    <PMID>14667076</PMID>
  </reference>
  <reference>
    <citation>Katchan B, Mamelak M, Hwang P. Alternating Hemiplegia of Childhood: Rationale for the use of Gammahydroxybutyrate, Reprints from the 10th International Child Neurology Congress, Montreal, June 2006.</citation>
  </reference>
  <reference>
    <citation>Kemp GJ, Taylor DJ, Barnes PR, Wilson J, Radda GK. Skeletal muscle mitochondrial dysfunction in alternating hemiplegia of childhood. Ann Neurol. 1995 Oct;38(4):681-4.</citation>
    <PMID>7574469</PMID>
  </reference>
  <reference>
    <citation>Kothare SV, Adams R, Valencia I, Faerber EC, Grant ML. Improved sleep and neurocognitive functions in a child with thalamic lesions on sodium oxybate. Neurology. 2007 Apr 3;68(14):1157-8.</citation>
    <PMID>17404202</PMID>
  </reference>
  <reference>
    <citation>Kyriakides T, Drousiotou A. No structural or biochemical evidence for mitochondrial cytopathy in a case of alternating hemiplegia of childhood. Ann Neurol. 1994 Nov;36(5):805-6.</citation>
    <PMID>7979233</PMID>
  </reference>
  <reference>
    <citation>Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004 Nov 1;27(7):1327-34.</citation>
    <PMID>15586785</PMID>
  </reference>
  <reference>
    <citation>Meyer S, Gottschling S, Georg T, Lothschütz D, Graf N, Sitzmann FC. Gamma-hydroxybutyrate versus chlorprothixene/phenobarbital sedation in children undergoing MRI studies. Klin Padiatr. 2003 Mar-Apr;215(2):69-73.</citation>
    <PMID>12677545</PMID>
  </reference>
  <reference>
    <citation>Micieli G, Sances G, Pacchetti C, Trucco M, Magri M, Piazza D. Flunarizine: a wide spectrum prophylactic for migraine headache. Int J Clin Pharmacol Res. 1984;4(3):239-45.</citation>
    <PMID>6490242</PMID>
  </reference>
  <reference>
    <citation>Mikati M. Alternating hemiplegia of childhood. Pediatr Neurol. 1999 Oct;21(4):764.</citation>
    <PMID>10580894</PMID>
  </reference>
  <reference>
    <citation>Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: clinical manifestations and long-term outcome. Pediatr Neurol. 2000 Aug;23(2):134-41.</citation>
    <PMID>11020638</PMID>
  </reference>
  <reference>
    <citation>Murali H, Kotagal S. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep. 2006 Aug;29(8):1025-9.</citation>
    <PMID>16944670</PMID>
  </reference>
  <reference>
    <citation>Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002 Jan-Feb;37(1):67-73.</citation>
    <PMID>11825860</PMID>
  </reference>
  <reference>
    <citation>Pöschl J, Kölker S, Bast T, Brüssau J, Ruef P, Linderkamp O, Bettendorf M. Gamma-hydroxybutyric acid sedation in neonates and children undergoing MR imaging. Klin Padiatr. 2007 Jul-Aug;219(4):217-9.</citation>
    <PMID>17638167</PMID>
  </reference>
  <reference>
    <citation>Priori A, Bertolasi L, Pesenti A, Cappellari A, Barbieri S. gamma-hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia. Neurology. 2000 Apr 25;54(8):1706.</citation>
    <PMID>10762526</PMID>
  </reference>
  <reference>
    <citation>Ricci S. Sleep studies of children with alternating hemiplegia of childhood. Alternating Hemiplegia of Childhood, edited by Andermann, Aicardi, and Vigevano. 1995;95-98.</citation>
  </reference>
  <reference>
    <citation>Rinalduzzi S, Valeriani M, Vigevano F. Brainstem dysfunction in alternating hemiplegia of childhood: a neurophysiological study. Cephalalgia. 2006 May;26(5):511-9.</citation>
    <PMID>16674759</PMID>
  </reference>
  <reference>
    <citation>Scrima L, Hartman PG, Johnson FH Jr, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990 Dec;13(6):479-90.</citation>
    <PMID>2281247</PMID>
  </reference>
  <reference>
    <citation>Sasaki M, Sakuragawa N, Osawa M. Long-term effect of flunarizine on patients with alternating hemiplegia of childhood in Japan. Brain Dev. 2001 Aug;23(5):303-5.</citation>
    <PMID>11504600</PMID>
  </reference>
  <reference>
    <citation>Silver K, Andermann F. Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment. Neurology. 1993 Jan;43(1):36-41.</citation>
    <PMID>8423908</PMID>
  </reference>
  <reference>
    <citation>Silver K, Andermann F. Alternating hemiplegia of childhood: treatment with flunarizine. Alternating Hemiplegia of Childhood, edited by F Andermann, J Aicardi, and F Vigevano. 1995;195-198.</citation>
  </reference>
  <reference>
    <citation>Suner S, Szlatenyi CS, Wang RY. Pediatric gamma hydroxybutyrate intoxication. Acad Emerg Med. 1997 Nov;4(11):1041-5.</citation>
    <PMID>9383489</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Kanavakis E, Xaidara A, Johnson JE, Leppert MF, Schlesinger-Massart MB, Ptacek LJ, Silver K, Youroukos S. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. Ann Neurol. 2004 Jun;55(6):884-7.</citation>
    <PMID>15174025</PMID>
  </reference>
  <reference>
    <citation>A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002 Feb 1;25(1):42-9.</citation>
    <PMID>11833860</PMID>
  </reference>
  <reference>
    <citation>U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004 Mar;5(2):119-23.</citation>
    <PMID>15033130</PMID>
  </reference>
  <reference>
    <citation>Verret S, Steele JC. Alternating hemiplegia in childhood: a report of eight patients with complicated migraine beginning in infancy. Pediatrics. 1971 Apr;47(4):675-80.</citation>
    <PMID>5089756</PMID>
  </reference>
  <reference>
    <citation>Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep. 2006 Sep;29(9):1189-94.</citation>
    <PMID>17040006</PMID>
  </reference>
  <reference>
    <citation>Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005 Oct 15;1(4):391-7.</citation>
    <PMID>17564408</PMID>
  </reference>
  <reference>
    <citation>Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005 Sep;6(5):415-21.</citation>
    <PMID>16099718</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <results_first_submitted>January 8, 2014</results_first_submitted>
  <results_first_submitted_qc>March 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2014</results_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kathryn Swoboda</investigator_full_name>
    <investigator_title>Associate Professor, Neurology and Pediatrics Director, Pediatric Motor Disorders Research Program</investigator_title>
  </responsible_party>
  <keyword>phase I/II study</keyword>
  <keyword>effects of sodium oxybate</keyword>
  <keyword>cohort of 6 children and young adults</keyword>
  <keyword>AHC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemiplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sodium Oxybate</title>
          <description>The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy.
Sodium Oxybate : dosage is by weight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Oxybate</title>
          <description>The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy.
Sodium Oxybate : dosage is by weight</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" lower_limit="1.1" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Duration of AHC Episodes</title>
        <time_frame>Week 7</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Safety Data During 5-day Hospitalization for Drug Dose Identification</title>
        <time_frame>Week 7</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported Side Effects During Home Drug Maintenance Phase</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Oxybate</title>
            <description>The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy.
Sodium Oxybate : dosage is by weight</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Side Effects During Home Drug Maintenance Phase</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Percentage of Time That Functional Status is Affected Due to Episodes</title>
        <time_frame>Week 14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaires</title>
        <time_frame>Week 14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mood and Behavior Questionnaires</title>
        <time_frame>Week 14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Skills Questionnaires</title>
        <time_frame>Week 14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Tests</title>
        <time_frame>Week 14</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sodium Oxybate</title>
          <description>The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy.
Sodium Oxybate : dosage is by weight</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness/vomit event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress Event</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Heat Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Desaturation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kathryn Swoboda</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-585-9717</phone>
      <email>taran@genetics.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

